Association Between the Degree of Inclusion of Components Identified on Fluorescein or Indocyanine Green Angiography in Target Spots and Relapse of Exudate in Eyes with Polypoidal Choroidal Vasculopathy and Typical Age-Related Macular Degeneration After Photodynamic Therapy

References

• Koh A, Lee WK, Chen L-J, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453–1464. doi:10.1097/IAE.0b013e31824f91e8
   PubMed Web of Science ®Google Scholar
• Tsuchihashi T, Mori K, Ueyama K, Yoneya S. Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration. Clin Ophthalmol. 2013;7:615–620. doi:10.2147/OPTH.S43566
   PubMedGoogle Scholar
• Teper S, Nowinska A, Pilat J, Wylegala E. Photodynamic therapy in VEGF inhibition non-responders-Pharmacogenetic study in age-related macular degeneration assessed with swept source optical coherence. Photodiagnosis Photodyn Ther. 2013;13:108–113. doi:10.1016/j.pdpdt.2016.01.006
   Web of Science ®Google Scholar
• Ranchod TM, Brucker AJ, Liu C, Cukras CA, Hopkins TB, Ying GS. Evaluation of actual vs expected photodynamic therapy spot size. Am J Ophthalmol. 2008;147(5):859–864. doi:10.1016/j.ajo.2008.11.010
   Web of Science ®Google Scholar
• Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP report. Arch Ophthalmol. 1999;117(10):1329–1345. doi:10.1001/archopht.117.10.1329
   PubMed Web of Science ®Google Scholar
• Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment–TAP and VIP report No. 2. Arch Ophthalmol. 2003;121(9):1253–1268.
   Google Scholar
• Wygnanski-Jaffe T, Desatnik H, Alhalel A, et al. ICG angiography-guided photodynamic therapy for large pigment epithelial detachments in age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2006;37(5):358–363. doi:10.3928/15428877-20060901-01
   Google Scholar
• Spaide RF, Donsoff I, Lam DL, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina. 2002;22(5):529–535. doi:10.1097/00006982-200210000-00001
   Web of Science ®Google Scholar
• Lee SC, Seong YS, Kim SS, Koh HJ, Kwon OW. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula. Ophthalmologica. 2004;218(3):193–201. doi:10.1159/000076844
   Web of Science ®Google Scholar
• Quaranta M, Maget-Faysse M, Coscas G. Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Am J Ophthalmol. 2002;134(2):277–280. doi:10.1016/S0002-9394(02)01516-7
   Web of Science ®Google Scholar
• Chan WM, Lam DS, Lai TY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. One-year results of a prospective case series. Ophthalmology. 2004;111(8):1576–1784. doi:10.1016/j.ophtha.2003.12.056
   PubMed Web of Science ®Google Scholar
• Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115(1):141–146. doi:10.1016/j.ophtha.2007.02.031
   Web of Science ®Google Scholar
• Yoshida Y, Kohno T, Yamamoto M, et al. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2013;57(3):283–293. doi:10.1007/s10384-013-0234-z
   PubMed Web of Science ®Google Scholar
• Eandi C, Ober M, Freund K, Slakter JS, Yannuzzi LA. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina. 2007;27(7):825–831. doi:10.1097/IAE.0b013e31804b3f70
   PubMed Web of Science ®Google Scholar
• Sheth J, Anantharaman G, Changra S, Gopalakrishnan M. Management of recalcitrant polypoidal choroidal vasculopathy by feeder vessel photocoagulation. Am J Ophthalmol Case Rep. 2018;9:112–115. doi:10.1016/j.ajoc.2018.01.031
   Google Scholar
• Georgalas I, Rouvas AA, Karagiannis DA, Kotsolis AI, Ladas ID. Photodynamic therapy of choroidal neovascularization with enlargement of the spot size to include the feeding complex. Clin Ophthalmol. 2009;3:13–16.
   Google Scholar
• Gomi F, Oshima Y, Mori R, et al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the Fujisan Study. Retina. 2014;35(8):1569–1576. doi:10.1097/IAE.0000000000000526
   Web of Science ®Google Scholar
• Hatz K, Prunte C. Changing from a pro re nata regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100(10):1341–1345. doi:10.1136/bjophthalmol-2015-307299
   Web of Science ®Google Scholar
• Adrean D, Chaili S, Ramkumar A, Pirouz A, Grant S. Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend stop protocol. Ophthalmology. 2018;125(7):1047–1053. doi:10.1016/j.ophtha.2018.01.012
   Web of Science ®Google Scholar
• Blinder KJ, Bradley S, Bressler NM, et al.; Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136(3):407–418. doi:10.1016/s0002-9394(03)00223-x
   Web of Science ®Google Scholar
• Gomi F, Sawa M, Mitarai K, Tsujikawa M, Tano Y. Angiographic lesion of polypoidal choroidal vasculopathy on indocyanine green and fluorescein angiography. Graefes Arch Clin Exp Ophthalmol. 2007;245(10):1421–1427. doi:10.1007/s00417-007-0564-y
   Web of Science ®Google Scholar
• Cheung CMG, Lai TYY, Chen SJ, et al. Understanding indocyanine green angiography in polypoidal choroidal vasculopathy. Retina. 2014;34(12):2397–2406. doi:10.1097/IAE.0000000000000255
   Web of Science ®Google Scholar
• Miets H, Merrill PT, Lambert HM, Font RL. Combined subretinal and subretinal pigment epithelium neovascular membranes in age-related macular degeneration: a clinicopathologic study of six cases. Ophthalmic Surg Lasers. 1997;28(8):645–652.
   Google Scholar
• Yanuzzi LA, Slakter JS, Sorenson RA, Guyer DR, Orlock DA. Digital indocyanine green videoangiography and choroidal neovascularization. Retina. 1992;12(3):191–223. doi:10.1097/00006982-199212030-00003
   Web of Science ®Google Scholar
• Guyer DR, Yannuzzi LA, Ladas I, Slakter JS, Sorenson JA, Orlock D. Indocyanine green-guided laser photocoagulation of focal spots at the edge of plaques of choroidal neovascularization. Arch Ophthalmol. 1996;114(6):693–697. doi:10.1001/archopht.1996.01100130685008
   Google Scholar
• Yoshida I, Sakamoto M, Sakai A, Maeno T. Effect of the duration of intraretinal or subretinal fluid on the response to treatment in undertreated age-related macular degeneration. J Ophthalmol. 2020;2020:5308597. doi:10.1155/2020/5308597
   Web of Science ®Google Scholar
• Ahlers C, Golbaz I, Stock G, et al. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology. 2008;115(8):e39–e46. doi:10.1016/j.ophtha.2008.05.017
   Google Scholar
• Kawamura A, Yuzawa M, Mori R, Haruyama M, Tanaka K. Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types. Acta Ophthalmol. 2013;91(6):e474–e481. doi:10.1111/aos.12110
   Web of Science ®Google Scholar
• Yang J, Yuan M, Wang E, Xia S, Chen Y. Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study. BMC Ophthalmol. 2019;19(1):237. doi:10.1186/s12886-019-1245-4
   Web of Science ®Google Scholar
• Yannuzzi LA, Hope-Ross M, Slakter JS, et al. Analysis of vascularized pigment epithelial detachments using indocyanine green videoangiography. Retina. 1994;14(2):99–113. doi:10.1097/00006982-199414020-00003
   Web of Science ®Google Scholar
• Meredith TA, Braley RE, Aaberg TM. Natural history of serous detachments of the retinal pigment epithelium. Am J Ophthalmol. 1979;88(4):643–651. doi:10.1016/0002-9394(79)90659-7
   Web of Science ®Google Scholar
• Kuehlewein L, Bansal M, Lenis TL, et al. Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration. Am J Ophthalmol. 2015;160(4):739–48.e2. doi:10.1016/j.ajo.2015.06.030
   PubMed Web of Science ®Google Scholar
• Youssfi-Rich A, Clement-Fernández F, García-Urtueta E, Clement-Corral A. Feeder vessel detection by means of dynamic indocyanine green angiography of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Soc Esp Ophthalmol. 2006;81(2):79–84. doi:10.4321/s0365-66912006000200007
   Google Scholar
• The Japanese age-related macular degeneration trial (JAT) study group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2003;136(6):1049–1061. doi:10.1016/S0002-9394(03)00576-2
   Web of Science ®Google Scholar